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Abstract Purpose: To evaluate
the association between concomitant
arginine-vasopressin (AVP)/hydro-
cortisone therapy and mortality in
severe septic shock patients. Meth-
ods: This retrospective study
included severe septic shock patients
treated with supplementary AVP. To
test the association between concom-
itant AVP/hydrocortisone use and
mortality, a multivariate regression
and Cox model (adjusted for admis-
sion year, initial AVP dosage and the
Sepsis-related Organ Failure Assess-
ment score before AVP) as well as a
propensity score-based analysis were
used. In both models, intensive care
unit (ICU) and 28-day mortality
served as outcome variables.
Results: One hundred fifty-nine
patients were included. Hydrocorti-
sone was administered to 76 (47.8%)
at a median daily dosage of 300
(200–300) mg. In the multivariate
logistic regression model, concomi-
tant use of AVP and hydrocortisone
was associated with a trend towards
lower ICU (OR, 0.51; CI 95%,
0.24–1.08; p = 0.08) and 28-day
(HR, 0.69; CI 95%, 0.43–1.08;
p = 0.11) mortality. The probability
of survival at day 28, as predicted by
the regression model, was signifi-
cantly higher in patients treated with
concomitant AVP and hydrocortisone
compared to those receiving AVP
without hydrocortisone (p = 0.001).
In a propensity score-based analysis,
ICU (45 vs. 65%; OR, 0.69; CI 95%
0.38–1.26; p = 0.23) and 28-day
mortality (35.5 vs. 55%; OR, 0.59; CI
95%, 0.27–1.29; p = 0.18) was not
different between patients treated
with (n = 40) or without concomitant
hydrocortisone (n = 40). Conclu-
sion: Concomitant AVP and
hydrocortisone therapy may be asso-
ciated with a survival benefit in septic
shock. An adequately powered, ran-
domised controlled trial appears
warranted to confirm these pre-
liminary, hypothesis-generating
results.
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Introduction
Addition of the neurohypophyseal hormone arginine-
vasopressin (AVP) to catecholamine vasopressors in
patients with septic shock can restore tissue perfusion
pressure [1], reduce norepinephrine requirements [1],
improve kidney function [2], and decrease the incidence
of catecholamine-associated adverse side effects [3]. In a
multicenter trial, supplementary AVP improved 28- and
90-day mortality in patients requiring 5–14 lg/min of
norepinephrine before the start of AVP, but not in patients
in need of higher norepinephrine dosages [4]. The latest
evidence suggests that concomitant use of arginine
vasopressin (AVP) and hydrocortisone may have benefi-
cial effects on septic shock survival [5, 6].
In this study, the association between concomitant
AVP and hydrocortisone therapy with mortality was
evaluated in a cohort of 159 patients suffering from severe
septic shock. We hypothesised that patients treated with
concomitant AVP and hydrocortisone had a lower mor-
tality than patients receiving AVP without hydrocortisone.
Materials and methods
This analysis was designed as a retrospective cohort study.
The study protocol was approved by the Ethics Committee
of the Innsbruck Medical University, Innsbruck/Austria
(UN3671). From 1999 until 2008, the medical charts of a
12-bed general and surgical intensive care unit at a tertiary
university teaching hospital were reviewed for patients
who fulfilled the following inclusion criteria: (1) presence
of septic shock as defined by the 1992 ACCP/SCCM
consensus conference [7] and (2) treatment with supple-
mentary AVP. Age \18 years, pregnancy, chronic
pathologies of the hypothalamic-pituitary-adrenal axis,
chronic corticosteroid therapy, duration of AVP infusion
\6 h, and AVP therapy for other indications than sepsis
related-cardiovascular failure were exclusion criteria.
Some patients included in this study have been analysed in
previous publications of our working group [1, 3, 8, 9].
Haemodynamic management
All patients were treated according to an institutional
haemodynamic protocol that served as a treatment
guideline [9]. Patients were routinely monitored with an
arterial and central venous line. A pulmonary artery or
trans-pulmonary thermodilution catheter was inserted at
the discretion of the attending physician. Fluid resusci-
tation was conducted according to the response of cardiac
filling pressures, stroke volume/cardiac index, and/or
arterial blood pressure to repetitive volume loading using
gelatine-based colloids or crystalloid solutions. If the
cardiac index remained \2–2.5 l/min/m2 and/or mixed/
central venous oxygen saturation \60–65% despite fluid
resuscitation and blood transfusions, milrinone and/or
epinephrine was continuously infused. Norepinephrine
was infused to increase mean arterial blood pressure
[60–70 mmHg. A supplementary AVP infusion at a
fixed dosage of 1–6 IU/h was added when the targeted
mean arterial blood pressure level could not be achieved
despite norepinephrine dosages exceeding 0.5 lg/kg/min
or catecholamine-induced side effects had occurred. No
patient received AVP as the sole vasopressor agent.
Continuous veno-venous haemofiltration was employed
for renal indications only. Except for the use of milrinone
and/or epinephrine as the first line inotrope, causative and
supportive sepsis therapy was performed in line with the
2004 and 2008 Surviving Sepsis Campaign guidelines
[10, 11]. Activated protein C was not administered in any
patient.
An ACTH test was not routinely performed, and
hydrocortisone was administered at the discretion of the
attending physician based on individual patient factors,
norepinephrine requirements, and contemporary scientific
evidence. If hydrocortisone was prescribed it was
administered as a continuous infusion at daily dosages
ranging between 100 and 300 mg. Hydrocortisone was
continued until catecholamine vasopressors could be
withdrawn and was then slowly tapered off over several
days.
Data documentation
The following data were extracted from medical records
of all patients: age, gender, body mass index, year of ICU
admission, infectious focus, the admission Simplified
Acute Physiology Score II [12], need for surgery, need for
continuous veno-venous haemofiltration, duration of
shock (defined as the need for any vasopressor drug)
following initiation of AVP therapy, length of intensive
care unit stay, as well as intensive care unit and 28-day
mortality. The Sepsis-related Organ Failure Assessment
(SOFA) score [13] was calculated from the most aberrant
haemodynamic, clinical, and laboratory variables before
the start of AVP and during the intensive care unit stay.
Hydrocortisone dosages as well as the time point of
hydrocortisone implementation (before or after start of
AVP infusion) were documented.
Statistical analysis
All statistical analyses were performed using the SPSS
software package (SPSS Inc., Chicago, IL). Group differ-
ences in demographic and clinical variables, as well as
mortality were assessed with the Mann-Whitney U or Fish-
er’s exact test, as applicable. To test the association between
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concomitant AVP and hydrocortisone use and mortality, two
models were used: first, a multivariate logistic regression
model and second a propensity score-based model.
Concomitant hydrocortisone therapy and variables
differing between patients with or without concomitant
hydrocortisone therapy were included as independent
covariates into the multivariate regression model.
Unadjusted group comparisons were performed for
demographic, clinical, and haemodynamic and labora-
tory variables before start of AVP therapy. The Fisher’s
exact or Mann-Whitney U-rank sum test was used for
group comparisons, as appropriate. Variables showing
group differences at an a-level \0.1 (year of admission
and initial AVP dosage) or for which a biological effect
was highly likely (age, SOFA score before start of AVP)
were subsequently included into the multivariate logistic
regression model to analyse the independent association
between concomitant hydrocortisone use and intensive
care unit mortality. For the analysis including 28-day
mortality, the same independent variables were included
into a Cox proportional hazard model accounting for the
survival time until day 28. To investigate whether timing
of hydrocortisone administration influenced the associa-
tion between concomitant AVP and hydrocortisone
therapy, addition of hydrocortisone before the start of
AVP was added into the models as a binary variable.
Kaplan-Meier curves were drawn to display and com-
pare (log-rank test) the probability of cumulative 28-day
survival based on the results of the Cox model. A linear
regression model adjusted for age, admission year, initial
AVP dosage, and SOFA score before the start of AVP
was used to determine the association between con-
comitant hydrocortisone therapy (independent variable)
and shock duration following the start of AVP (depen-
dent variable) in study patients experiencing shock
reversal.
A propensity score [14] was established using the
following covariates: admission year, age, SOFA score
before the start of AVP, norepinephrine dose before the
start of AVP, and initial AVP dose. This score was then
used to couple patients with concomitant hydrocortisone
and AVP therapy as well as patients with supplementary
AVP infusion but no concomitant hydrocortisone therapy.
For the coupling process optimal 1:1 matching (4–1
digits) was used. No replacements for previously matched
patients were allowed. Intensive care unit and 28-day
mortality was then compared between the two patient
groups (concomitant AVP and hydrocortisone therapy
versus supplementary AVP infusion without concomitant
hydrocortisone therapy) using a conditional logistic
regression model for intensive care unit mortality and a
Cox model stratified to matched pairs for 28-day
mortality.
A significance level of p \ 0.05 was applied for all
comparisons. Data are presented as median values with
interquartile ranges (IQR), if not otherwise indicated.
Results
During the observation period, 159 septic shock patients
who were treated with a supplementary AVP infusion
fulfilled the inclusion criteria for this study (Table 1).
Hydrocortisone was administered to 76 patients (47.8%)
at a median daily dosage of 300 (200–300) mg. The year
of admission differed significantly between groups and
affected the study population’s intensive care unit and
28-day mortality (Electronic Supplementary Material
Fig. 1). Haemodynamic and laboratory variables before
the start of AVP therapy are summarised in Table 2. In
both groups, AVP was initiated at 4 (2–4) IU/h
(p = 0.05). In 34 patients (44.7%), hydrocortisone was
initiated before and in 42 patients (55.3%) after the start
of AVP therapy.
In the multivariate logistic regression model (adjusted
for admission year, initial AVP dosage and the SOFA
score before start of AVP), concomitant use of AVP and
hydrocortisone was associated with a trend towards lower
28-day and intensive care unit mortality (Table 3). The
probability of survival at day 28 as predicted by the
multivariate regression model was significantly higher in
patients treated with AVP and hydrocortisone compared
to those receiving supplementary AVP without concom-
itant hydrocortisone (Fig. 1). There was no difference in
intensive care unit (OR, 0.71; CI 95%, 0.27–1.88;
p = 0.49) or 28-day mortality (HR, 0.8; CI 95%,
0.45–1.58; p = 0.52) between patients in whom con-
comitant hydrocortisone therapy was started before or
after initiation of supplementary AVP. Concomitant
hydrocortisone and AVP therapy was not associated with
the duration of shock following the start of AVP therapy
(standardised ß-coefficient, -0.1; p = 0.52).
Eighty of 159 study patients (50%) could be included
into the propensity score-based analysis (concomitant
AVP and hydrocortisone therapy, n = 40; supplementary
AVP therapy without concomitant hydrocortisone ther-
apy, n = 40). The number of patients coupled on 4, 3, 2,
and 1 digits of the propensity score was 2 (2.5%), 14
(17.5%), 48 (60%), and 16 (20%), respectively. In the
propensity score-based analysis, intensive care unit (45
vs. 65%; OR, 0.69; CI 95% 0.38–1.26; p = 0.23), and
28-day mortality (35.5 vs. 55%; HR, 0.59; CI 95%,
0.27–1.29; p = 0.18) was not different between patients
treated with or without concomitant hydrocortisone.
Discussion
The results of this retrospective cohort study suggest that
concomitant use of AVP and hydrocortisone could be
associated with a survival benefit in septic shock patients.
This association was not affected by the timing of
hydrocortisone administration in relation to initiation of
1434
AVP therapy. Our findings are in line with the results of
two recent studies in septic shock patients reporting a
potential benefit of concomitant AVP and hydrocortisone
therapy [5, 6]. In a post-hoc analysis of the multicentre
VASST study, Russell et al. [5] detected a significant
interaction between AVP and hydrocortisone therapy, as
well as a mortality benefit in corticosteroid-treated septic
shock patients who received AVP compared to those
treated with corticosteroids and norepinephrine alone.
In contrast to our analysis, corticosteroids other than
hydrocortisone were administered in the VASST study
[5]. Furthermore, patients analysed in our study consis-
tently suffered from severe septic shock and may
therefore not be comparable to the VASST population in
which a survival benefit for AVP was observed only in
patients with less but not those with more severe septic
shock. In a retrospective, case control study, more
patients receiving concomitant AVP and hydrocortisone
Table 1 Characteristics of study patients
AVP ? HC AVP p-value
n 76 83
Age (years) 69 (57-78) 66 (57-75) 0.2
Male sex n (%) 47 (61.8) 55 (66.3) 0.62
BMI (kg/m2) 25 (22-27) 26 (23-30) 0.33
Admission year 2004 (2002-2006) 2001 (2000-2004) \0.001b
Infectious focus n (%) 0.5
Abdominal 39 (51.3) 32 (38.6)
Pulmonary 17 (22.4) 26 (31.3)
Wound/soft tissue 5 (6.6) 9 (10.8)
Urogenital 3 (3.9) 2 (2.4)
Catheter 2 (2.6) 1 (1.2)
Others 10 (13.2) 13 (15.7)
Admission SAPS II (pts) 52 (42-63) 50 (39-63) 0.61
Need for surgery n (%) 55 (72.4) 62 (74.7) 0.86
Need for CVVHF n (%) 46 (60.5) 53 (63.9) 0.74
NE dose before AVP (l/kg/min) 0.66 (0.39-1.19) 0.8 (0.42-1.25) 0.22
SOFA score preAVP (pts) 15 (13-16) 15 (13-17) 0.34
Initial AVP dose lU/h 4 (2-4) 4 (2-4) 0.05
Max SOFA score (pts) 15 (13-17) 16 (14-18) 0.25
Shock durationa (h) 142 (100-257) 173 (104-300) 0.59
Length of ICU stay (days) 17 (5-30) 14 (6-26) 0.4
28-day mortality n (%) 36 (47.4) 51 (61.4) 0.08
ICU mortality n (%) 40 (52.6) 57 (68.7) 0.05
Data are presented as median values with interquartile ranges, if not
otherwise indicated
AVP ? HC combined arginine vasopressin and hydrocortisone
therapy, AVP arginine vasopressin, BMI body mass index, SAPS
Simplified Acute Physiology Score, NE norepinephrine, SOFA
Sequential Organ Failure Assessment, preAVP before the start of
arginine vasopressin infusion, SAPS Simplified Acute Physiology
Score, CVVHF continuous veno-venous haemofiltration, ICU
intensive care unit
a After the start of AVP (only intensive care unit survivors
included)
b Significant difference between groups
Table 2 Haemodynamic and laboratory variables before the start of AVP
AVP ? HC AVP p-value
n 76 83
Heart rate (bpm) 110 (100-120) 110 (98-125) 1
MAP (mmHg) 55 (50-65) 60 (50-65) 0.61
CVP (mmHg) 13 (11-15) 13 (11.5-16) 0.27
NE dose (lg/kg/min) 0.66 (0.39-1.19) 0.8 (0.42-1.25) 0.22
Milrinone dose (lg/kg/min) 0.4 (0.25-0.57) 0.43 (0.25-0.6) 0.27
pH 7.29 (7.23-7.38) 7.31 (7.24-7.38) 0.9
Base deficit (mmol/l) -4.7 (-7.6 to -0.4) -3.9 (-8 to -0.7) 0.89
Lactate (mg/dl) 35 (19-59) 39 (18-68) 0.84
SOFA score (pts) 15 (13-16) 15 (13-17) 0.34
Data are presented as median values with interquartile ranges, if not
otherwise indicated
AVP ? HC combined arginine vasopressin and hydrocortisone
therapy, AVP arginine vasopressin, MAP mean arterial blood
pressure, CVP central venous pressure, CI cardiac index, SVR
systemic vascular resistance, NE norepinephrine, SOFA Sequential
Organ Failure Assessment
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were alive without vasopressor support at day 7 compared
to subjects receiving AVP but no hydrocortisone [6].
Since this study included only patients treated with a
supplementary AVP infusion, it is conceivable that a
potential survival benefit of concomitant AVP and
hydrocortisone therapy was attributable to hydrocortisone
alone, thus occurring independently of the addition of
AVP. More rapid shock reversal and better survival have
been reported for hydrocortisone therapy in septic shock
patients requiring escalating vasopressor dosages or those
with an insufficient response to corticotropin [15, 16].
However, Russell et al. [5] observed that the probability
of 28-day survival was higher in norepinephrine-treated
septic shock patients receiving concomitant AVP and
corticosteroids than in those receiving corticosteroids but
no AVP. Several mechanisms could explain the beneficial
effects of a concomitant AVP and hydrocortisone therapy
in septic shock patients. These mechanisms potentially
include multiple interactions between the hypothalamic-
pituitary-adrenal and hypothalamic-posterior pituitary-
vasopressin axes [17–19] as well as restoration of vaso-
pressinergic receptor sensitivity by corticosteroids [20].
Considering that our study included 159 septic shock
patients, it was under-powered to investigate a mortality
difference, and its results must be interpreted with cau-
tion. Furthermore, it needs to be remembered that
although both a propensity score-based model and a
multivariate regression/Cox model may identify inde-
pendent associations between pre-defined variables, they
cannot prove a causative relationship. Since patients
treated with AVP but no hydrocortisone may not have
survived long enough to receive hydrocortisone, hetero-
geneity in the timing of hydrocortisone administration
could have further introduced a lead time bias into our
analysis. This precludes conclusive comparisons of hae-
modynamic and laboratory variables between groups after
initiation of AVP. Finally it needs to be acknowledged
that this is a retrospective study implying the risk of
missing data sets and undetected group differences at
baseline. Since no management protocol was consistently
adhered to in our study population but treatment was
based on institutional guidelines, we cannot exclude that
survival differences between groups arose from diverse
patient managements. Finally, mortality rates were found
to differ between admission years. Although all statistical
analyses were adjusted for the year of admission, this
cannot safely exclude the influence of all confounding
Table 3 Multivariate regression model to predict ICU and 28-day mortality
Variable type Unit Wald Odds ratio 95% CI p-value
ICU mortality
SOFA score before AVP Continuous Per point 9.28 1.24 1.08–1.43 0.002
Concomitant HC therapy Categorical 3.09 0.51 0.24–1.08 0.08
Age Continuous Per year 2.43 1.02 0.99–1.05 0.12
Admission year Categorical 0.38 1.05 0.91–1.2 0.54
Initial AVP dosage Continuous Per IU/h 0.37 1.09 0.82–1.45 0.54
28-day mortality Hazard ratio
SOFA score before AVP Continuous Per point 6.89 1.13 1.03–1.24 0.009
Age Continuous Per year 6.02 1.02 1–1.04 0.01
Concomitant HC therapy Categorical 2.61 0.69 0.43–1.08 0.11
Initial AVP dosage Continuous Per IU/h 1.12 1.11 0.92–1.33 0.29
Admission year Categorical 0.75 1.04 0.95–1.14 0.39
ICU intensive care unit, CI confidence interval, SOFA Sequential Organ Failure Assessment Score, HC hydrocortisone, AVP arginine
vasopressin
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Fig. 1 Probability of cumulative 28-day survival as predicted by
the adjusted logistic regression model for septic shock patients
receiving arginine vasopressin with or without concomitant hydro-
cortisone. AVP arginine vasopressin, HC hydrocortisone;
*predicted by the logistic regression model adjusted for age,
admission year, initial AVP dosage, and the Sepsis-related Organ
Failure Assessment score before the start of AVP
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factors related to changes occurring during the observa-
tion period.
In conclusion, concomitant AVP and hydrocortisone
therapy may be associated with a survival benefit in septic
shock. An adequately powered, randomised, controlled
trial appears warranted to confirm these preliminary,
hypothesis-generating results.
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